<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20191" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cyanotic Heart Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ossa Galvis</surname>
            <given-names>Maria M.</given-names>
          </name>
          <aff>Lincoln Medical and Mental Health Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhakta</surname>
            <given-names>Rupal T.</given-names>
          </name>
          <aff>University of Arkansas</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tarmahomed</surname>
            <given-names>Abdulla</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mendez</surname>
            <given-names>Magda D.</given-names>
          </name>
          <aff>Lincoln Medical Center/Weil Cornell</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maria Ossa Galvis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rupal Bhakta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdulla Tarmahomed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Magda Mendez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20191.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Congenital heart disease (CHD) are structural abnormalities of the heart or intrathoracic great vessels occurring during fetal development. CHD is the most common type of birth defect and the leading cause of death in children with congenital malformations. CHD can be subdivided in non-cyanotic CHD and cyanotic CHD which is also called critical congenital heart disease (CCHD). CCHD can be further classified into 3 different types of lesions: right heart obstructive lesions, left heart obstructive lesions, and mixing lesions. This activity reviews the workup of cyanotic heart disease and describes the role of health professionals working together to manage this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the types of cyanotic heart disease.</p></list-item><list-item><p>Review the presentation of cyanotic heart disease.</p></list-item><list-item><p>Summarize the treatment of cyanotic heart disease.</p></list-item><list-item><p>Outline the workup of cyanotic heart disease and describes the role of health professionals working together to manage this condition.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20191&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20191">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20191.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Congenital heart disease (CHD) are structural abnormalities of the heart or intrathoracic great vessels occurring during fetal development. CHD is the most common type of birth defect and the leading cause of death in children with congenital malformations. CHD can be subdivided in non-cyanotic CHD and cyanotic CHD which is also called critical congenital heart disease (CCHD). CCHD can be further classified into 3 different type of lesions: right heart obstructive lesions, left heart obstructive lesions, and mixing lesions.<xref ref-type="bibr" rid="article-20191.r1">[1]</xref><xref ref-type="bibr" rid="article-20191.r2">[2]</xref><xref ref-type="bibr" rid="article-20191.r3">[3]</xref><xref ref-type="bibr" rid="article-20191.r4">[4]</xref></p>
      </sec>
      <sec id="article-20191.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of CHD is still largely unknown. Many cases of CHD are multifactorial and result from a combination of genetic predisposition and environmental risk factors. CCHD is usually isolated and sporadic, but it can also be associated with genetic syndromes. Approximately 15% to 20% of infants with CCHD are related to known chromosomal abnormalities, most of these are aneuploidies (trisomy 21, 13, and 18 and Turner syndrome). Potential environmental risk factors include maternal illnesses, including diabetes and phenylketonuria, maternal exposure to toxins or drugs and viral infections during pregnancy.</p>
      </sec>
      <sec id="article-20191.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Congenital heart disease (CHD) affects 8 to 9 per 1000 live births, and approximately 25% are considered CCHD. The incidence of CHD increase to 2% to 6% for a second pregnancy after the birth of a child with CHD or if a parent is affected. Tetralogy of Fallot (TOF) is the most common CCHD (5% of all CCHD). Transposition of the great arteries (TGA) is the second most common CCHD (approximately 2% of all CCHD), and it is the most common CCHD manifesting in the first week after birth. It is estimated that 35% of infant deaths due to congenital malformations are related to cardiovascular anomalies.</p>
      </sec>
      <sec id="article-20191.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>In fetal circulation, gas exchange occurs in the placenta. From the placenta, oxygenated blood travels through the umbilical vein into the Inferior vena cava (IVC) through the ductus venosus (DV), bypassing the liver circulation. In the heart, most of the oxygenated blood is shunted from the right atrium to the left atrium through the foramen ovale (FO). From the left atrium, blood is pumped to the left ventricle and into the aorta to reach systemic circulation. A small portion of blood is pumped from the right atrium to right ventricle and the pulmonary artery. From the pulmonary artery, blood is shunted to the aorta through the ductus arteriosus (DA), bypassing the lungs. Deoxygenated blood return to the placenta by the umbilical arteries.<xref ref-type="bibr" rid="article-20191.r5">[5]</xref><xref ref-type="bibr" rid="article-20191.r6">[6]</xref><xref ref-type="bibr" rid="article-20191.r7">[7]</xref></p>
        <p>CCHD is silent in fetal life because fetus receives oxygenated blood from the placenta and either the FO or DA can increase systemic blood flow. After DA and FO closure soon after birth, most CCHD become symptomatic. Cyanosis may be caused by persistence of fetal circulation, right-to-left shunting across the FO and ductus DA in the presence of pulmonary outflow tract obstruction or persistent pulmonary hypertension of the newborn.</p>
      </sec>
      <sec id="article-20191.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The diagnosis of CCHD might be missed prenatally, or during birth hospitalization; therefore, clinicians should be aware of its clinical manifestation during the first weeks of life. History alone may be not sufficient to differentiate between congenital heart disease, pulmonary disease, an inborn error of metabolism and sepsis. Additional physical exam findings and diagnostic evaluations would be necessary to identify CCHD. Thorough family history must also be obtained giving the genetic component of CCHD.</p>
        <p>The history associated with CCHD include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Irritability or decreased level of activity</p>
          </list-item>
          <list-item>
            <p>Diaphoresis and crying with feedings</p>
          </list-item>
          <list-item>
            <p>Decrease amount of formula per feed</p>
          </list-item>
          <list-item>
            <p>History of longer time per breastfeed</p>
          </list-item>
          <list-item>
            <p>Poor weight gain</p>
          </list-item>
          <list-item>
            <p>Fast and/or irregular breathing</p>
          </list-item>
          <list-item>
            <p>Bluish or purple discoloration of the skin or mucous membranes</p>
          </list-item>
          <list-item>
            <p>Older children may present with exercise intolerance, including dyspnea, diaphoresis cyanosis or palpitations during exercise</p>
          </list-item>
        </list>
        <p>Physical findings associated with CCHD include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Cyanosis</p>
          </list-item>
          <list-item>
            <p>Tachypnea</p>
          </list-item>
          <list-item>
            <p>Increased work of breathing</p>
          </list-item>
          <list-item>
            <p>Pulmonary edema</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Heart murmur</p>
          </list-item>
          <list-item>
            <p>Hepatomegaly (Liver edge located more than 2.5 cm below the right costal margin)</p>
          </list-item>
          <list-item>
            <p>Weak femoral pulses</p>
          </list-item>
          <list-item>
            <p>Signs of poor perfusion or shock</p>
          </list-item>
          <list-item>
            <p>Lethargy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20191.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<italic toggle="yes">
<bold>Fetal Echocardiogram</bold>
</italic>
</p>
        <p>A fetal echocardiogram should be performed in all fetuses with a suspected cardiac abnormality noted on obstetric ultrasound. Prenatal ultrasound can identify structural heart disease. However, the sensitivity of congestive heart disease detection is highly variable, depends on the operator expertise, gestational age fetal position, and type of cardiac defect.<xref ref-type="bibr" rid="article-20191.r8">[8]</xref><xref ref-type="bibr" rid="article-20191.r9">[9]</xref><xref ref-type="bibr" rid="article-20191.r10">[10]</xref></p>
        <p>
<italic toggle="yes">
<bold>Pulse Oximetry Screening</bold>
</italic>
</p>
        <p>The pulse oximetry screening for CCHD in newborns was added to the Recommended Uniform Screening Panel in the United States in 2011, and it was endorsed by the American Academy of Pediatrics in 2012. Screening is performed in the well-infant nursery when the baby is at least 24 hours of age, or as late as possible if the baby is to be discharged from the hospital before 24 hours of life. Earlier screening can lead to false-positive results.</p>
        <p>CCHD screening will only identify cardiac lesions with the right to left shunt and cyanosis. Screening is recommended in the right hand and either foot. Positive screen result includes one of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Any Oxygen Saturation less than 90%</p>
          </list-item>
          <list-item>
            <p>Oxygen Saturation less than 95% in both extremities, on 3 measures, each separated by 1 hour</p>
          </list-item>
          <list-item>
            <p>More than 3% absolute difference in oxygen saturation between the right hand and foot on 3 measures, each separated by 1 hour</p>
          </list-item>
        </list>
        <p>Differential cyanosis, lower oxygen saturation in the lower extremities, can be seen in PPHN with interrupted aortic arch, and coarctation of the aorta. Reverse cyanosis, lower oxygen saturation in the right hand, is a manifestation of TGA with concurrent CoA or IAA. Positive pulse oximetry screen will require prompt evaluation, including 4-limb blood pressure measurement, chest radiography, ECG, and echocardiography.</p>
        <p>The seven primary CCHD screening targets are hypoplastic left heart syndrome (HLHS), pulmonary atresia (PA), Tetralogy of Fallot (TOF), total&#x000a0;anomalous pulmonary venous return (TAPVR), transposition of great arteries (TGA), tricuspid atresia, and truncus arteriosus. Secondary screening targets are coarctation of the aorta (CoA), interrupted aortic arch (IAA), critical aortic stenosis, DORV, Ebstein anomaly and single ventricle complex. CCHD screening would miss about 15% of all CCHD cases; COA/IAA, TAPVR and TOF cases are the most common conditions missed. A failed newborn screen may also indicate other disease processes, such as pulmonary hypertension, primary pulmonary parenchymal disease, or hemoglobinopathies.</p>
        <p>
<italic toggle="yes">
<bold>Hyperoxia Test </bold>
</italic>
</p>
        <p>Hyperoxia test is the initial method to distinguish CCHD from pulmonary disease. The test consists in measuring an arterial blood gas at room air and 100% inspired oxygen after 10 minutes. Neonates with congenital heart disease are usually not able to increase PaO2 above 100 mm Hg during 100% oxygen administration. In patients with pulmonary disease, PaO2 generally increased greater than or equal to 100 mm Hg with 100% oxygen as ventilation-perfusion discrepancies are overcome. A positive result indicates the cardiac origin and further cardiac workup is indicated to rule out CCHD.</p>
        <p>
<bold>
<italic toggle="yes">Electrocardiogram (ECG)</italic>
</bold>
</p>
        <p>ECG identifies rhythm abnormalities, auricular or ventricular hypertrophy, dextrocardias, or abnormal axis deviation.</p>
        <p>
<italic toggle="yes">
<bold>Chest X-Ray</bold>
</italic>
</p>
        <p>Chest x-ray indicates whether pulmonary blood flow is increased, normal, or decreased. Can identify specific unique findings of CCHD - &#x0201c;egg-shaped&#x0201d; heart seen in TGA, &#x0201c;snowman&#x0201d; in TAPVR, &#x0201c;boot-shaped&#x0201d; heart in TOF, extreme cardiomegaly in Ebstein&#x02019;s anomaly.&#x000a0; May also be helpful in the differentiation of pulmonary and cardiac disease.</p>
        <p>
<italic toggle="yes">
<bold>Two-Dimensional Echocardiography</bold>
</italic>
</p>
        <p>The definitive noninvasive test to determine the presence of CHD. Echocardiography with Doppler can determine the degree and direction of the shunt and the gradient of outflow tract obstruction.</p>
        <p><italic toggle="yes"><bold>Additional Imaging Modalities</bold></italic>&#x000a0;</p>
        <p>These include cardiac catheterization and angiography, magnetic resonance imaging (MRI) and CT scanning, to further visualize cardiac anatomy in preparation for cardiac surgery.</p>
        <p>
<bold>Summary of CCHD Evaluation Findings </bold>
</p>
        <p>
<italic toggle="yes">
<bold>
<bold>Right Heart Obstructive Lesions</bold>
</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary atresia (PA)</p>
          </list-item>
          <list-item>
            <p>Tricuspid atresia</p>
          </list-item>
          <list-item>
            <p>Tetralogy of Fallot (TOF)</p>
          </list-item>
          <list-item>
            <p>Critical pulmonary stenosis</p>
          </list-item>
        </list>
        <p>Right heart obstructive lesions lead to decrease pulmonary flow. PDA supplies pulmonary blood flow by shunting blood from the aorta to the pulmonary artery. There is a right-to-left intracardiac shunt. PFO shunts deoxygenated blood from the right atrium to the left atrium, and when &#x000a0;VSD is present, blood is shunted from the right ventricle to the left ventricle.</p>
        <p>
<italic toggle="yes">Screening Findings</italic>
</p>
        <p>Positive CCHD screening with oxygen saturation less than 90% without a difference in oxygenation between upper and lower extremities. Hyperoxia test is positive in these conditions. Chest x-ray shows decreased or normal pulmonary blood flow. ECG is an important tool to differentiate among these lesions. Left axis (0 to 90 degrees) is characteristic of pulmonary atresia; left superior axis (0 to -90 degrees) for tricuspid atresia, and right axis (90 to 180 degrees) for critical pulmonary stenosis and TOF.</p>
        <p>
<italic toggle="yes">
<bold>Left Heart Obstructive Lesions</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypoplastic left heart syndrome (HLHS)</p>
          </list-item>
          <list-item>
            <p>Interrupted aortic arch (IAA)/coarctation of the aorta (CoA)</p>
          </list-item>
          <list-item>
            <p>Critical aortic stenosis.</p>
          </list-item>
        </list>
        <p>Left heart obstructive lesions lead to decreased systemic flow. PDA supplies systemic blood flow by shunting blood from the pulmonary artery to the aorta. There is a Left-to-right intracardiac shunt with secondary pulmonary over-circulation. PFO shunts oxygenated blood from the left atrium to the right atrium, and when VSD is present, blood is shunted from the left ventricle to the right ventricle.</p>
        <p>
<italic toggle="yes">Screening Findings</italic>
</p>
        <p>Positive CCHD screening with oxygen saturation less than 95%; there is a greater than 3% difference between upper and lower oxygen saturation. Negative hyperoxia test. Positive BP gradient between upper and lower extremities is seen in this lesions, except for HLHS. Chest x-ray shows increase pulmonary blood flow. ECG shows normal axis for a newborn (90 to 180 degrees), except for critical aortic stenosis which has left axis for a newborn (0 to 90 degrees).</p>
        <p>
<italic toggle="yes">
<bold>Mixing Lesions</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Transposition of the great arteries (TGA)</p>
          </list-item>
          <list-item>
            <p>Total anomalous pulmonary venous return (TAPVR)</p>
          </list-item>
          <list-item>
            <p>Truncus arteriosus</p>
          </list-item>
        </list>
        <p>Cyanosis presents from mixing pulmonary and systemic blood flow. These conditions are considered Ductal-independent lesions. PDA is not required, but they can present with or without PFO.&#x000a0;</p>
        <p>
<italic toggle="yes">Screening Findings</italic>
</p>
        <p>Positive CCHD screening with oxygen saturation less than 95%. There is no difference between upper and lower oxygen saturation, except for d-TGA with pulmonary hypertension or coarctation of the aorta, where O2 saturation is higher in the foot than in the right arm. Negative Hyperoxia Test. Chest x-ray shows normal to increased pulmonary blood flow. ECG shows normal axis for a newborn (90 to 180 degrees).</p>
      </sec>
      <sec id="article-20191.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>After fetal echocardiogram makes a diagnosis of CCHD, specialized delivery room planning in a tertiary care center&#x000a0;is required for prompt evaluation and management.<xref ref-type="bibr" rid="article-20191.r11">[11]</xref><xref ref-type="bibr" rid="article-20191.r12">[12]</xref><xref ref-type="bibr" rid="article-20191.r13">[13]</xref></p>
        <p>At birth, if a CCHD is suspected and cardiac investigation or pediatric cardiologist is not easily available, appropriate stabilization, oxygen therapy, infusion of prostaglandin E1, and prompt transportation to a tertiary care center is necessary. Prostaglandin E1 is useful for ductal-dependent lesions as bridging therapy for further interventions or cardiac surgery. Approximately 25% of children born with a CHD will need heart surgery or other interventions to survive. Balloon atrial septostomy is performed acutely in cases of TGA, allowing adequate blood mixing, and in cases of pulmonary hypertension, relieving right-sided pressures. The patient can undergo early corrective surgery or, in some cases, undergo palliation with a shunt prior to their corrective surgery. After the cardiac surgery is performed, it is essential that the primary source of each postoperative problem be identified and treated, for example, respiratory failure, cardiac rhythm disorders, heart failure, renal failure, seizures, thromboembolism and stroke, hemolysis, infections, postpericardiotomy syndrome, among others.</p>
        <p>Routine immunizations should be given. Careful consideration for the timing of administration of live-virus vaccination is required in patients who are potential candidates for cardiopulmonary bypass, heart or heart-lung transplantation. Prophylaxis against the respiratory syncytial virus is recommended during respiratory syncytial virus season in infants with unrepaired congenital heart disease and significant hemodynamic abnormalities. Subacute bacterial endocarditis (SAB) prophylaxis is recommended for patients undergoing dental procedures for patients with high risk of adverse outcomes according to 2007 Statement of the American Heart Association (AHA). Other management considerations include treatment of iron-deficiency anemia, close observation for excessive polycythemia, avoidance of dehydration to prevent the risk of stroke. Parents who have a child with congenital heart disease require counseling regarding the probability of a cardiac malformation occurring in subsequent children.</p>
      </sec>
      <sec id="article-20191.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary parenchymal disease</p>
          </list-item>
          <list-item>
            <p>Pulmonary hypertension</p>
          </list-item>
          <list-item>
            <p>Sepsis</p>
          </list-item>
          <list-item>
            <p>Inborn error of metabolism</p>
          </list-item>
          <list-item>
            <p>Hemoglobinopathy (methemoglobinemia)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20191.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>One-year survival for infants with CCHDs has improved over time; however, mortality remains high. About 75% of babies born with a CCHD are expected to survive to 1 year of age. About 69% of babies born with critical CHDs are expected to survive to 18 years of age. Children with CCHD are at an increased risk for developmental delay and disability, heart rhythm disorders, heart failure, sudden cardiac arrest or stroke.</p>
      </sec>
      <sec id="article-20191.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management of cyanotic heart disease is with an interprofessional team consisting of a neonatologist, pediatrician, cardiologist, cardiac surgeon, intensivist and NICU nurses. The treatment depends on the type of heart defect. While some infants may have an isolated heart defect, others may have many other systemic anomalies that also need assessment. Thus, it is important to have the pediatrician and a geneticist involved in the care of these infants.</p>
      </sec>
      <sec id="article-20191.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20191&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20191">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/child-health/cyanotic-heart-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20191">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20191/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20191">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20191.s13">
        <title>References</title>
        <ref id="article-20191.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rabinowitz</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Physiologic diagnosis of congenital heart disease in cyanotic neonates.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>274</fpage>
            <page-range>274-283</page-range>
            <pub-id pub-id-type="pmid">30730315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20191.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Segura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gatzoulis</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Where are we with coronary artery disease for the cyanotic patient with congenital heart disease?</article-title>
            <source>Int J Cardiol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>15</day>
            <volume>277</volume>
            <fpage>108</fpage>
            <page-range>108-109</page-range>
            <pub-id pub-id-type="pmid">30665555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20191.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohammad Nijres</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Samuel</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Vettukattil</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Subclinical atherosclerosis in patients with cyanotic congenital heart disease.</article-title>
            <source>Int J Cardiol</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>282</volume>
            <fpage>44</fpage>
            <pub-id pub-id-type="pmid">30704770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20191.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schaan</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Feltez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schaan</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Pellanda</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>FUNCTIONAL CAPACITY IN CHILDREN AND ADOLESCENTS WITH CONGENITAL HEART DISEASE.</article-title>
            <source>Rev Paul Pediatr</source>
            <year>2019</year>
            <season>Jan-Mar</season>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-72</page-range>
            <pub-id pub-id-type="pmid">30624535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20191.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chikkabyrappa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahadevaiah</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Buddhe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alsaied</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tretter</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Common Arterial Trunk: Physiology, Imaging, and Management.</article-title>
            <source>Semin Cardiothorac Vasc Anesth</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>225</fpage>
            <page-range>225-236</page-range>
            <pub-id pub-id-type="pmid">30596352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20191.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wise-Faberowski</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Asija</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McElhinney</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Tetralogy of Fallot: Everything you wanted to know but were afraid to ask.</article-title>
            <source>Paediatr Anaesth</source>
            <year>2019</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>475</fpage>
            <page-range>475-482</page-range>
            <pub-id pub-id-type="pmid">30592107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20191.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bigdelian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ghaderian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sedighi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Surgical repair of Tetralogy of Fallot following primary palliation: Right ventricular outflow track stenting versus modified Blalock-Taussig shunt.</article-title>
            <source>Indian Heart J</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>70 Suppl 3</volume>
            <issue>Suppl 3</issue>
            <fpage>S394</fpage>
            <page-range>S394-S398</page-range>
            <pub-id pub-id-type="pmid">30595296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20191.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van De Bruaene</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Droogne</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>De Meester</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Troost</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gewillig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Budts</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Management of acute heart failure in adult patients with congenital heart disease.</article-title>
            <source>Heart Fail Rev</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-14</page-range>
            <pub-id pub-id-type="pmid">29277859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20191.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tulloh</surname>
                <given-names>RMR</given-names>
              </name>
              <name>
                <surname>Medrano-Lopez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Checchia</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Stapper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sumitomo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gorenflo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jung Bae</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Juanico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gil-Jaurena</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Farha</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dodge-Khatami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Notario</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wegzyn</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>CHD and respiratory syncytial virus: global expert exchange recommendations.</article-title>
            <source>Cardiol Young</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>1504</fpage>
            <page-range>1504-1521</page-range>
            <pub-id pub-id-type="pmid">28619123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20191.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Filippo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Infective endocarditis prophylaxis in congenital heart disease].</article-title>
            <source>Presse Med</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>46</volume>
            <issue>6 Pt 1</issue>
            <fpage>606</fpage>
            <page-range>606-611</page-range>
            <pub-id pub-id-type="pmid">28576635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20191.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bedair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Iriart</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>EDUCATIONAL SERIES IN CONGENITAL HEART DISEASE: Tetralogy of Fallot: diagnosis to long-term follow-up.</article-title>
            <source>Echo Res Pract</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>R9</fpage>
            <page-range>R9-R23</page-range>
            <pub-id pub-id-type="pmid">30557849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20191.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ismail</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Almazmi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Khokhar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>AlMadani</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hadadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hijazi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kabbani</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Shaath</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Elbarbary</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effects of protocol-based management on the post-operative outcome after systemic to pulmonary shunt.</article-title>
            <source>Egypt Heart J</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>271</fpage>
            <page-range>271-278</page-range>
            <pub-id pub-id-type="pmid">30591742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20191.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasir-Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cordina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liew</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McCluskey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Celermajer</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The eye in CHD.</article-title>
            <source>Cardiol Young</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>981</fpage>
            <page-range>981-985</page-range>
            <pub-id pub-id-type="pmid">30043722</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
